Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2019’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

– The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects

– The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“21st Century Therapeutics Inc

Absynth Biologics Ltd

Acticule Life Sciences Ltd

AEON Medix Inc

AimMax Therapeutics Inc

Alchemia Ltd

Allergan Plc

AlphaMab Co Ltd

Amicrobe Inc

Amprologix Ltd

AnyGen Co Ltd

Aphios Corp

Aridis Pharmaceuticals Inc

Arietis Corp

Armata Pharmaceuticals Inc

Atriva Therapeutics GmbH

Aurigene Discovery Technologies Ltd

Basilea Pharmaceutica Ltd

Bharat Biotech Ltd

Biomendics LLC

BioPlx Microbiomics Pvt Ltd

Bioseka UAB

Bioversys AG

Botanix Pharmaceuticals Ltd

Cadila Pharmaceuticals Ltd

Cantab Anti-infectives Ltd

Cellics Therapeutics Inc

Citius Pharmaceuticals Inc

Combioxin SA

Crestone Inc

CrystalGenomics Inc

CSA Biotechnologies LLC

Curza Global LLC

Daiichi Sankyo Co Ltd

Debiopharm International SA

DeNovaMed Inc

Destiny Pharma Plc

Emerald Bioscience Inc

ESA Patentverwertungsagentur Sachsen-Anhalt GmbH

GangaGen Inc

Global BioLife Inc Ltd

Helix BioMedix Inc

Helperby Therapeutics Group Ltd

Hsiri Therapeutics LLC

HSRx Group

HyPharm GmbH

Idorsia Pharmaceutical Ltd

Inimmune Corp

Insmed Inc

Instituto Biomar SA

Integrated BioTherapeutics Inc

ioGenetics Inc

Johnson & Johnson

KBP BioSciences Co Ltd

Kurobe LLC

Kyorin Pharmaceutical Co Ltd

Lakewood-Amedex Inc

Lead Discovery Center GmbH

LegoChem Biosciences Inc

Lysimmune BioScience

Madam Therapeutics BV

Matrisys Bioscience Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

MGB Biopharma Ltd

Microbiotix Inc

MicuRx Pharmaceuticals Inc

Nabriva Therapeutics Plc

Naicons Srl

Neupharma Srl

Novabiotics Ltd

NovaDigm Therapeutics Inc

Novalex Therapeutics Inc

NovoBiotic Pharmaceuticals LLC

Olymvax Biopharmaceuticals Inc

Opal Biosciences Ltd

Oppilotech Ltd

Oragenics Inc

Oryn Therapeutics

Ovensa Inc

Oxford Drug Design Ltd

Peptineo

Phico Therapeutics Ltd

PolyPid Ltd

Procarta Biosystems Ltd

Prommune Inc

Q2 Pharma Ltd

QureTech Bio AB

Recce Ltd

Roivant Sciences Ltd

Sano Chemicals Inc

Savara Inc

SciBac Inc

Sealife PHARMA GMBH

Sentinella Pharmaceuticals Inc

Shanghai Space Peptides Pharmaceutical Co Ltd

Sinsa Labs Inc

Soligenix Inc

Sorrento Therapeutics Inc

Stealth Biologics LLC

Synspira LLC

Taejoon Pharm Co Ltd

TAXIS Pharmaceuticals Inc

Telephus Medical LLC

Tetraphase Pharmaceuticals Inc

TGV Laboratories Inc

TGV-Inhalonix Inc

Therapeutic Systems Research Laboratories Inc

Theravance Biopharma Inc

Trellis Bioscience Inc

Union Therapeutics AS

Valevia UK Ltd

Venomyx Inc

Viosera Therapeutics

Vitas Pharma Research Pvt Ltd

VLP Biotech Inc

Wockhardt Ltd

XBiotech Inc

Yungjin Pharm Co Ltd”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Overview 7

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Development 8

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Therapeutics Assessment 38

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Companies Involved in Therapeutics Development 48

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Drug Profiles 82

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Dormant Projects 346

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Discontinued Products 358

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Product Development Milestones 359

Appendix 370

List of Tables

“List of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by 21st Century Therapeutics Inc, H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Absynth Biologics Ltd, H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Acticule Life Sciences Ltd, H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AEON Medix Inc, H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by AimMax Therapeutics Inc, H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline by Alchemia Ltd, H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Dormant Projects, H2 2019

H2 2019

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Discontinued Products, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports